RxDoctor Payments Data

Mario Pelletier, MD

Internal Medicine · Kissimmee, FLNPI 1457310724

Payments from drug & device makers

$3,053in general payments, 2019–2025

Across 111 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$673
  • GSK$203
  • Sanofi-aventis U.S. LLC$122
  • Novo Nordisk$93
  • Exact Sciences$88
  • plus $251 from 10 others

What the payments were for

  • Food & beverage$3,02599%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,053 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,981
Medicare patients
149
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,435
JanuviaSitagliptin Phosphate45$45,262
MounjaroTirzepatide30$42,945
OzempicSemaglutide24$42,911
EliquisApixaban31$40,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$38,240
JardianceEmpagliflozin24$37,547
EntrestoSacubitril/Valsartan17$21,653
XareltoRivaroxaban66$19,596
FarxigaDapagliflozin Propanediol23$19,389
JanumetSitagliptin Phos/Metformin Hcl13$18,555
SymbicortBudesonide/Formoterol Fumarate39$15,297
LinzessLinaclotide12$14,535
TradjentaLinagliptin17$13,882
MyrbetriqMirabegron12$12,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$42,91124 claims
PfizerEliquis$14$40,62831 claims
GSKTrelegy Ellipta$203$38,24039 claims
AstraZenecaFarxiga, Symbicort$673$34,68762 claims
AbbVieLinzess$36$14,53512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →